Celecoxib to Treat Macular Degeneration in Patients Receiving Photodynamic Therapy - Related Studies

Celecoxib to Treat Macular Degeneration in Patients Receiving Photodynamic Therapy

This study has been completed.

Study NCT00043680. Last updated on March 3, 2008. Information provided by National Institutes of Health Clinical Center (CC)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Macular Degeneration

2	More general conditions related to this trial
		Eye Diseases
		Retinal Degeneration
		Retinal Diseases

3	Interventions listed in this trial
		Celecoxib

4	More general drug interventions related to this trial
		Analgesics
		Analgesics, Non-Narcotic
		Anti-Inflammatory Agents
		Anti-Inflammatory Agents, Non-Steroidal
		Antirheumatic Agents
		Central Nervous System Agents
		Cyclooxygenase Inhibitors
		Enzyme Inhibitors
		Molecular Mechanisms of Pharmacological Action
		Peripheral Nervous System Agents
		Pharmacologic Actions
		Physiological Effects of Drugs
		Sensory System Agents
		Therapeutic Uses

5	Sponsors listed in this trial
		National Eye Institute (NEI)